DE 098

Drug Profile

DE 098

Alternative Names: Anti-APO-1 monoclonal antibody; ARG-098; DE-098

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor
  • Developer Argenes; Santen Pharmaceutical
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD95 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 28 Jul 2015 No recent reports of development identified - Phase-I/II for Rheumatoid arthritis in Europe (Intra-articular)
  • 28 Jul 2015 No recent reports of development identified - Phase-II for Rheumatoid arthritis in Japan (Intra-articular)
  • 03 Dec 2010 Phase-II clinical trials in Rheumatoid arthritis in Japan (Intra-articular) (JapicCTI111469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top